Clinical trials
Phase 2/3 Stomach Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
50 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 3 |
| 2012 | 6 |
| 2013 | 2 |
| 2015 | 5 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 15 |
| Completed | 12 |
| Recruiting | 10 |
| Terminated | 5 |
| Active, not recruiting | 4 |
| Not yet recruiting | 4 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hebei Medical University | 3 |
| Bristol-Myers Squibb | 2 |
| Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2 |
| RemeGen Co., Ltd. | 2 |
| ALX Oncology Inc. | 1 |
| ASLAN Pharmaceuticals | 1 |
| Auron Healthcare GmbH | 1 |
| Australasian Gastro-Intestinal Trials Group | 1 |
| BIRENDRA KUMAR SAH | 1 |
| Blokhin's Russian Cancer Research Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Stomach Neoplasms | 50 |
| Gastrointestinal Neoplasms | 3 |
| Neoplasms | 3 |
| Pancreatic Neoplasms | 3 |
| Colonic Neoplasms | 2 |
| Esophageal Neoplasms | 2 |
| Liver Neoplasms | 2 |
| Peritoneal Neoplasms | 2 |
| Colorectal Neoplasms | 1 |
| Diabetes Mellitus | 1 |
Trials
Showing 1 to 25 of 50. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.